158. Tuberous sclerosis Clinical trials / Disease details


Clinical trials : 108 Drugs : 67 - (DrugBank : 17) / Drug target genes : 35 - Drug target pathways : 118

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-006997-27-BE
(EUCTR)
01/06/201129/05/2009A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) - N/AA randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) - N/A This study will evaluate the antitumor activity of RAD001 versus placebo in patientswith subependymal giant cell astrocytomas (SEGA) associated with TuberousSclerosis Complex (TSC).Trade Name: Certican 1 mg tablets
Product Name: RAD001
Product Code: RAD001
INN or Proposed INN: everolimus
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
99Belgium;Netherlands;Germany;United Kingdom;Italy